Reply to "Infliximab therapy in hematologic malignancies: handle with care" 2012;97(8):e26

Fungal Infections in Pediatric Patients with Hematologic Malignancies

As the data on the epidemiology and outcome of fungal infections in children with hematologic cancer are limited especially in Iran, this study was aimed to delineate the epidemiologic features and outcome of fungal infections in this population. The medical records of all children with hematologic malignancies diagnosed with a fungal infection from 2005 to 2010 at a tertiary pediatric hospita...

Treating hematologic malignancies: barriers to care.

Targeted therapy for hematologic malignancies.

BACKGROUND The introduction of monoclonal antibodies, either as native molecules or conjugated to radioisotopes or other toxins, has led to new therapeutic options for patients with hematologic malignancies. In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders. METHODS The aut...

Interleukin-2 in therapy of hematologic malignancies.

T HE ARTICLE BY Gisselbrecht et all in this issue of Blood describes the activity of single-agent interleukin-2 (IL-2) in a heterogeneous group of previously treated patients with malignant non-Hodgkin’s lymphoma (NHL), Hodgkin’s disease, and cutaneous T-cell lymphoma (CTCL). The number of patients within each of the defined groups is relatively small, and the confidence intervals surrounding t...

End-of-life care in children with hematologic malignancies

Introduction Hematologic malignancies (HM) represent the most common neoplasms in childhood. Despite improved overall survival rates, they are still a major contributor to cancer death in children. Aims To determine the proportion of children with HM in pediatric palliative care (PPC) and to identify the clinical characteristics and symptoms in comparison to children with extracranial solid t...